BRAF and neoplasm: As showed by a prospective study on 38 RAS-BRAF wild-type mCRC patients who received a third-line treatment with irinotecan and cetuximab, early CTC-negative and CTC status changes assessment during treatment were significantly associated with tumor response and better PFS and OS, predicting treatment failure in advance compared to imaging-based tools [25].